Author response for "A Phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha 2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia not achieving a deep molecular response (MR 4.5) – AGMT_CML 1"
Sonja Heibl(Klinikum Wels-Grieskirchen), Josef Thaler(Thrombolysis in Myocardial Infarction Study Group), Dominik Wolf(Universität Innsbruck), Richard Greil(Paracelsus Medical University), Thomas Lion(Ludwig Boltzmann Institute for Cancer Research), Gerald Webersinke(AGO Austria), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Thomas Melchardt(Paracelsus Medical University), Stefan Schmidt(Innsbruck Medical University), Thomas Kuehr(Klinikum Wels-Grieskirchen), Gudrun Piringer(Klinikum Wels-Grieskirchen)
Cited by 0
Related Papers
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
|Blood|2011|448